Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Deferred Tax Liability (2016 - 2020)

Historic Non-Current Deferred Tax Liability for Summit Therapeutics (SMMT) over the last 5 years, with Q3 2020 value amounting to $2.1 million.

  • Summit Therapeutics' Non-Current Deferred Tax Liability changed N/A to $2.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $2.1 million for FY2019, which is N/A changed from last year.
  • According to the latest figures from Q3 2020, Summit Therapeutics' Non-Current Deferred Tax Liability is $2.1 million.
  • Over the past 5 years, Summit Therapeutics' Non-Current Deferred Tax Liability peaked at $2.1 million during Q3 2020, and registered a low of -$3.4 million during Q1 2018.
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was -$2.0 million (2019), whereas its average is -$1.4 million.
  • Per our database at Business Quant, Summit Therapeutics' Non-Current Deferred Tax Liability crashed by 58140.99% in 2018 and then surged by 3639.81% in 2019.
  • Summit Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at -$811000.0 in 2016, then rose by 7.52% to -$750000.0 in 2017, then tumbled by 195.38% to -$2.2 million in 2018, then grew by 9.46% to -$2.0 million in 2019, then surged by 205.1% to $2.1 million in 2020.
  • Its last three reported values are $2.1 million in Q3 2020, -$2.2 million for Q1 2020, and -$2.0 million during Q4 2019.